|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Early and late outcome after elective cardiac surgery in patients with cirrhosis显示文摘 | Philippe Bizouarn Antoine Ausseur Pascal Desseigne Yann Le Teurnier Bertrand Nougarede Michel Train Jean Luc Michaud | 1999 | The Annals of Thoracic Surgery1999，，5： | 1 |
| 2 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Conroy T Desseigne F Yehou M | 2011 | N Engl J Med2011，364，19： | 1 |
| 3 | FOLFIRINOXversus gemcitabine for metastatic pancreatic cancer显示文摘 | CONROY T DESSEIGNE F YCHOU M | 2011 | N Engl JMed2011，364，19： | 1 |
| 4 | Randomized phase III trial comparing FOLFIRINOX versus gemcitabine as first-line treatment for metastatic pancteatic adenocarcinoma:Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial显示文摘 | Conroy T Desseigne F Y chou M | 2010 | J Clin2010，28，： | 1 |
| 5 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Conroy T Desseigne F Ychou M | 2011 | N Engl J Med2011，364，19： | 1 |
| 6 | Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial 显示文摘 | Assenat E Desseigne F Thezenas S | 2011 | Oncologist2011，16，11： | 1 |
| 7 | FOLFIRINOX ver-sus gemcitabine for metastatic pancreatic cancer 显示文摘 | Conroy T Desseigne F Ychou M | 2011 | N Engl J Med2011，364，19： | 1 |
| 8 | Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer 显示文摘 | Wang Q Lasset C Desseigne F | 1999 | Hum Genet1999，105，12： | 1 |
| 9 | Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer:a phase Ⅱ trial显示文摘 | Assenat E Desseigne F Thezenas S | 2011 | Oncologist2011，16，： | 1 |
| 10 | FOLFIRINOX versus gemeitabine for metastatic pancreatic cancer 显示文摘 | Conroy T Desseigne F Yehou M | 2011 | N Engl J Med2011，364，19： | 1 |
| 11 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Conroy T Desseigne F Ychou M | 2011 | NEngl J Med2011，364，19： | 1 |
| 12 | Randomized phase Ⅲ trial comparing FOLFIRINOX (F: 5FU/ leucovorin (LV) , irinotecan (I) , and oxaliplatin (O) ) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocar cinoma ( MPA ) : Preplanned interim analysis results of the PRODIGE 4/ ACCORD 11 trial 显示文摘 | Conroy T Desseigne F Ychou M | 2010 | J Clin Oncol2010，28，15： | 1 |
| 13 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | CONROY T DESSEIGNE F YCHOU M | 2011 | N EnglJ Med2011，364，19： | 1 |
| 14 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Conroy T Desseigne F Ychou M | 2011 | N Engl J Med2011，364，： | 1 |
| 15 | Cetuximab plus FOLFIRINOX (ERBIRINOX)as first-line treatment for unresectable metastatic colorectal cancer:a phase Ⅱ trial显示文摘 | Assenat E Desseigne F Thezenas S | 2011 | Oncolagist2011，16，11： | 1 |
| 16 | FOLFIRINOX ver- sus gemcitabine for metastatic pancreatic carcinoma显示文摘 | Conroy T Desseigne F Yehou M | 2011 | N Engl J Md2011，364，19： | 1 |
| 17 | Preparation de I acide di -isopropylsalicylique et de ses derives显示文摘 | Desseigne G | 1948 | Bull Soc Fr1948，6870，： | 1 |
| 18 | Prevalence of germline mutations of hMLH1,hMSH2,hPMS1,hPMS2,and hMSH6genes in 75 French kindreds with nonpolyposis colorectal cancer显示文摘 | Wang Q Lasset C Desseigne F | 1999 | Hum Genet1999，105，12： | 1 |
| 19 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 显示文摘 | Conroy T Desseigne F Ychou M | 2011 | N Engl J Med2011，364，19： | 1 |
| 20 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer显示文摘 | Conroy T Desseigne F Ychou M | | 0，，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员